Table 3. Multivariable analyses for... | American Society of Hematology

Table 3.

Multivariable analyses for acute GVHD grade 2 to 4 and Rel/prog and association with combined biological models

HLA-DPB1 matching	Categories	aGVHD grade 2 to 4 (N = 860, events = 297)*					Rel/prog (N = 837, events = 302)*†
HLA-DPB1 matching	Categories	Events/n	HR	95% CI		P	Events/n	HR	95% CI		P
TCE3.1 and PIRCHE II	Matched	67/250	1.00	—			96/237	1.00	—
	Nonpermissive, no PIRCHE II	13/51	0.85	0.47	1.53	.58	20/49	0.87	0.53	1.42	.57
	Nonpermissive, PIRCHE II	102/237	1.73	1.27	2.37	*<.001*	71/235	0.65	0.47	0.88	*.005*
	Permissive, no PIRCHE II	31/91	1.28	0.84	1.97	.25	36/95	0.88	0.59	1.29	.50
	Permissive, PIRCHE II	84/231	1.40	1.01	1.93	*.04*	79/221	0.77	0.57	1.03	.08
TCE4.1 and PIRCHE II	Matched	67/250	1.00	—			96/237	1.00	—
	Nonpermissive, no PIRCHE II	25/91	0.93	0.59	1.48	.77	33/92	0.75	0.50	1.12	.15
	Nonpermissive, PIRCHE II	131/312	1.67	1.24	2.25	*.001*	94/311	0.64	0.48	0.85	*.002*
	Permissive, no PIRCHE II	19/51	1.48	0.89	2.48	.13	23/52	1.15	0.72	1.82	.56
	Permissive, PIRCHE II	55/156	1.35	0.94	1.93	.10	56/145	0.85	0.61	1.19	.34
Expression and PIRCHE II	Matched	67/250	1.00	—			96/237	1.00	—
	R-high, no PIRCHE II‡	9/13	NI	NI	NI	NI	4/11	NI	NI	NI	NI
	R-high, PIRCHE II	62/155	1.72	1.21	2.44	*.002*	40/149	0.61	0.42	0.88	*.008*
	R-low, no PIRCHE II	10/42	0.86	0.44	1.67	.66	16/42	0.72	0.42	1.23	.23
	R-low, PIRCHE II	43/121	1.30	0.88	1.92	.19	56/119	0.95	0.68	1.32	.75
Expression and TCE3.1	Matched	67/250	1.00	—			96/237	1.00	—
	R-high, nonpermissive	39/89	1.87	1.26	2.80	*.002*	26/86	0.73	0.47	1.13	.15
	R-high, permissive	32/79	1.79	1.17	2.73	*.008*	18/74	0.55	0.33	0.92	*.02*
	R-low, nonpermissive	11/36	1.10	0.58	2.10	.77	19/35	1.00	0.61	1.65	1.00
	R-low, permissive	42/127	1.21	0.82	1.79	.34	53/126	0.85	0.61	1.20	.36
Expression and TCE4.1	Matched	67/250	1.00	—			96/237	1.00	—
	R-high, nonpermissive	43/98	1.88	1.28	2.77	*<.001*	29/95	0.71	0.47	1.09	.12
	R-high, permissive	28/70	1.76	1.13	2.75	*.01*	15/65	0.54	0.31	0.93	.03
	R-low, nonpermissive	27/89	1.11	0.71	1.74	.65	35/91	0.71	0.48	1.05	.08
	R-low, permissive	26/74	1.28	0.81	2.02	.29	37/70	1.16	0.79	1.70	.45

HLA-DPB1 matching	Categories	aGVHD grade 2 to 4 (N = 860, events = 297)*					Rel/prog (N = 837, events = 302)*†
HLA-DPB1 matching	Categories	Events/n	HR	95% CI		P	Events/n	HR	95% CI		P
TCE3.1 and PIRCHE II	Matched	67/250	1.00	—			96/237	1.00	—
	Nonpermissive, no PIRCHE II	13/51	0.85	0.47	1.53	.58	20/49	0.87	0.53	1.42	.57
	Nonpermissive, PIRCHE II	102/237	1.73	1.27	2.37	*<.001*	71/235	0.65	0.47	0.88	*.005*
	Permissive, no PIRCHE II	31/91	1.28	0.84	1.97	.25	36/95	0.88	0.59	1.29	.50
	Permissive, PIRCHE II	84/231	1.40	1.01	1.93	*.04*	79/221	0.77	0.57	1.03	.08
TCE4.1 and PIRCHE II	Matched	67/250	1.00	—			96/237	1.00	—
	Nonpermissive, no PIRCHE II	25/91	0.93	0.59	1.48	.77	33/92	0.75	0.50	1.12	.15
	Nonpermissive, PIRCHE II	131/312	1.67	1.24	2.25	*.001*	94/311	0.64	0.48	0.85	*.002*
	Permissive, no PIRCHE II	19/51	1.48	0.89	2.48	.13	23/52	1.15	0.72	1.82	.56
	Permissive, PIRCHE II	55/156	1.35	0.94	1.93	.10	56/145	0.85	0.61	1.19	.34
Expression and PIRCHE II	Matched	67/250	1.00	—			96/237	1.00	—
	R-high, no PIRCHE II‡	9/13	NI	NI	NI	NI	4/11	NI	NI	NI	NI
	R-high, PIRCHE II	62/155	1.72	1.21	2.44	*.002*	40/149	0.61	0.42	0.88	*.008*
	R-low, no PIRCHE II	10/42	0.86	0.44	1.67	.66	16/42	0.72	0.42	1.23	.23
	R-low, PIRCHE II	43/121	1.30	0.88	1.92	.19	56/119	0.95	0.68	1.32	.75
Expression and TCE3.1	Matched	67/250	1.00	—			96/237	1.00	—
	R-high, nonpermissive	39/89	1.87	1.26	2.80	*.002*	26/86	0.73	0.47	1.13	.15
	R-high, permissive	32/79	1.79	1.17	2.73	*.008*	18/74	0.55	0.33	0.92	*.02*
	R-low, nonpermissive	11/36	1.10	0.58	2.10	.77	19/35	1.00	0.61	1.65	1.00
	R-low, permissive	42/127	1.21	0.82	1.79	.34	53/126	0.85	0.61	1.20	.36
Expression and TCE4.1	Matched	67/250	1.00	—			96/237	1.00	—
	R-high, nonpermissive	43/98	1.88	1.28	2.77	*<.001*	29/95	0.71	0.47	1.09	.12
	R-high, permissive	28/70	1.76	1.13	2.75	*.01*	15/65	0.54	0.31	0.93	.03
	R-low, nonpermissive	27/89	1.11	0.71	1.74	.65	35/91	0.71	0.48	1.05	.08
	R-low, permissive	26/74	1.28	0.81	2.02	.29	37/70	1.16	0.79	1.70	.45

.05 > P ≥ .01 are shown in bold and italic; P < .01 are shown in bold, italic, and underlined. Significant covariables retained for relapse/progression (Rel/prog): European Society for Blood and Marrow Transplantation risk score, graft manipulation, and transplant center. Significant covariables retained for aGVHD: HLA-DRB3/4/5 matching, graft manipulation, and transplant center. CI, confidence interval; D, donor; Events, number of events in the risk category for the specified outcome; n, number of patients in the risk category for the specified outcome; R, recipient.

The number of patients/events for the regressions with expression is N = 579/191 and 558/212 for aGVHD ≥2 and Rel/prog, respectively.

†

Patients with nonmalignant disorder are excluded from analyses on relapse.

‡

Not interpretable (NI) because of the very small number of patients in this group.

View Large

This Feature Is Available To Subscribers Only